Document is current
Any future updates will be listed below
-
Authors
Hussain, Khiyam http://orcid.org/0000-0002-6705-4412
Liu, Rena
Smith, Rosanna C. G.
Müller, Kri T. J.
Ghorbani, Mohammadmersad
Macari, Sofia
Cleary, Kirstie L. S.
Oldham, Robert J.
Foxall, Russell B.
James, Sonya
Booth, Steven G.
Murray, Tom
Dahal, Lekh N.
Hargreaves, Chantal E.
Kemp, Robert S.
Longley, Jemma
Douglas, James
Markham, Hannah
Chee, Serena J.
Stopforth, Richard J.
Roghanian, Ali
Carter, Matthew J.
Ottensmeier, Christian H.
Frendéus, Bjorn
Cutress, Ramsey I.
French, Ruth R.
Glennie, Martin J.
Strefford, Jonathan C.
Thirdborough, Stephen M.
Beers, Stephen A.
Cragg, Mark S. http://orcid.org/0000-0003-2077-089X
-
Funding
Funding for this research was provided by:
Cancer Research UK (A24721)
National Centre for the Replacement, Refinement and Reduction of Animals in Research (15402-106217)
Cancer Research UK (C328/A25139)
Cancer Research UK (C24563/A25171)
- License Information
-
More Information
Article History
Received: 4 October 2021
Accepted: 20 February 2022
First Online: 7 April 2022
Declarations
:
: Anonymized leukocyte cones were sourced from healthy adult donors attending blood donation clinics at the National Blood Service (Southampton, UK). The use of leukocyte cones for this work was approved by the University of Southampton Faculty of Medicine Ethics Committee and the East of Scotland Research Ethics Service, Tayside, UK, Research ethical committee (REC) reference number: 16/ES/0048. Clinical samples from 6 anonymized mesothelioma patients (REC reference number: 13/SW/0128) and Donor matched Renal cell carcinoma (RCC) and non-cancerous healthy kidney tissue samples were obtained from resected kidneys from 5 RCC patients (REC reference number: 17/WA/0241). Lymphocele samples were sourced from 3 anonymized breast cancer patents (REC reference number: 10/H0504/73, for breast cancer patient samples). Peripheral blood samples were taken from Chronic Lymphoblastic Leukemia (CLL) patients and anonymized before experimental use (REC reference number: 10/H0504/187). These aforementioned clinical samples were released from the Human Tissue Authority Licensed University of Southampton, Cancer Sciences Tissue Bank, as approved by the Southampton and South West Hampshire Research Ethics Committee (REC reference: 280/99). All informed consent for the use of human material was provided in accordance with the Declaration of Helsinki.Mice were used in these studies as the least sentient species with an immune system comparable to humans. Following approval by local ethical committees, reporting to the Home Office Animal Welfare Ethical Review Board (AWERB) at the University of Southampton, in vivo experiments were conducted under UK Home Office Project licenses P81E129B7 and P4D9C89EA.
: A.R. receives funding from BioInvent International. Research by R.I.C is supported by use of equipment to measure body composition provided by SECA through a model industry collaborative agreement (mICA) with University Hospital Southampton. M.J.G previously acted as a consultant to a number of biotech companies and receives institutional payments and royalties from antibody patents and licenses. J.C.S has received funding from Roche. S.A.B acts as a consultant for a number of biotech companies and has received institutional support for grants and patents from BioInvent. M.S.C. acts as a consultant for a number of biotech companies, being retained as a consultant for BioInvent International and has received research funding from BioInvent, GSK, UCB, iTeos, and Roche.
